<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2022.101007</article-id><article-id pub-id-type="publisher-id">JBM-114765</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Prevalence and Genotyping of Human Papillomavirus among Women in the Departments of Niari and Bouenza, Republic of the Congo
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Parfait</surname><given-names>Christy Nganga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Luc</surname><given-names>Magloire Anicet Boumba</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Candyse</surname><given-names>Paola Lemba Tsimba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Franck</surname><given-names>Gaëtan Loubanou Tchibinda</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Roch</surname><given-names>Bredin Bissala Nkounkou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eben</surname><given-names>Ebatetou Ataboho</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ghislain</surname><given-names>Loubano-Voumbi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Donatien</surname><given-names>Moukassa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Faculté des Sciences et Techniques, Université Marien NGOUABI, Brazzaville, Congo</addr-line></aff><aff id="aff2"><addr-line>Laboratoire d’Analyses Médicales et Morphologiques, H&amp;amp;ocirc;pital Général de Loandjili, Pointe-Noire, Congo</addr-line></aff><aff id="aff1"><addr-line>Faculté des Sciences de la Santé, Université Marien NGOUABI, Brazzaville, Congo</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>01</month><year>2022</year></pub-date><volume>10</volume><issue>01</issue><fpage>64</fpage><lpage>77</lpage><history><date date-type="received"><day>18,</day>	<month>December</month>	<year>2021</year></date><date date-type="rev-recd"><day>18,</day>	<month>January</month>	<year>2022</year>	</date><date date-type="accepted"><day>21,</day>	<month>January</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Human papillomaviruses (HPV) are at the origin of many mucosal, benign or malignant skin pathologies. Some so-called high-risk genotypes, especially types 16 and 18, are involved in the genesis of cervical cancer, one of the most common cancers in women. To determine the prevalence of HPV infections and to identify oncogenic genotypes circulating in the departments of Niari and Bouenza. A total of 207 cervical samples collected between 2019 and 2020 were studied. Cervico vaginal smears were performed on all samples for cytological analysis, and HPV DNA detection and genotyping were performed on GeneXpert. The average age of the women who participated in this study was 43.67 &#177; 12.31 years in Niari and 38.29 &#177; 10.52 in Bouenza with age intervals ranging from 18 to 80 years. Cytological analysis of these samples reported the following prevalences: Normal diagnosed in 89.58% (186/207) cases, ASCUS in 5.31% (11/207) cases, LSIL in 2.89% (6/207) cases, and ICC in 1.93% (4/207) cases. The prevalence of HPV infection was detected in 83.54% (66/186) of women without lesions, 6.32% (5/11) of ASCUS women and 10.12% (8/10) of women with cytological abnormalities [5.06% (4/6) LSIL, and 5.06% (4/4) ICC]. In total, 79 of the 207 women in our study tested positive for one or more HPV-HR types, or 38.16%. In the department of Niari 37.5% (48/128) women tested positive for HPV, and in the department of Bouenza 39.24% (31/79) tested positive for HPV. Multiple infections ranged from two to more than three strains of HPV. No statistically significant association was observed between socio-demographic characteristics and genotyping (p &gt; 0.05). On the other hand, HPV-HR prevalence varied significantly according to cervical cytology (p = 0.001). The results obtained show the predominance of HPV 16 in women in these two departments of Congo.
 
</p></abstract><kwd-group><kwd>CCU</kwd><kwd> HPV</kwd><kwd> FCV</kwd><kwd> Niari</kwd><kwd> Bouenza</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Cervical cancer is the most common cancer in women in developing countries. It is estimated to be responsible for nearly 260,000 deaths per year, about 80% of which are in developing countries [<xref ref-type="bibr" rid="scirp.114765-ref1">1</xref>]. In sub-Saharan Africa, it accounts for 22.2% of all cancer cases in women [<xref ref-type="bibr" rid="scirp.114765-ref2">2</xref>], and is the leading cause of death from female cancer in Africa behind breast cancer [<xref ref-type="bibr" rid="scirp.114765-ref3">3</xref>]. However, persistent infection with certain oncogenic papillomavirus (HPV) types is firmly established as the necessary cause of most precancerous and cancerous epithelial lesions of the cervix and a variable fraction of neoplastic lesions of the vulva, vagina, anus, penis and oropharynx [<xref ref-type="bibr" rid="scirp.114765-ref4">4</xref>].</p><p>Indeed, these HPV infections are among the most prevalent in the world [<xref ref-type="bibr" rid="scirp.114765-ref5">5</xref>], with a global incidence of more than 30 million new cases per year. Thus, HPV infection is one of the most common sexually transmitted viral infections [<xref ref-type="bibr" rid="scirp.114765-ref6">6</xref>].</p><p>In Congo, about 214 deaths from cervical cancer occur per year and are diagnosed each year (estimates for 2020) [<xref ref-type="bibr" rid="scirp.114765-ref7">7</xref>]. Indeed, cervical cancer ranks as the 1<sup>st</sup> cause of death among women who die from cancer in Congo and is the 3<sup>rd</sup> leading cause of cancer death in women aged 15 to 44 years [<xref ref-type="bibr" rid="scirp.114765-ref7">7</xref>], and age-adjusted incidence and mortality rates are estimated at 25.2 and 13.0 per 100,000 women, respectively [<xref ref-type="bibr" rid="scirp.114765-ref8">8</xref>].</p><p>In addition, the local context shows a lack of scientific information on the molecular epidemiology of HPV infections and its complications in the departments of Niari and Bouenza. This information is crucial in order to provide virological data in the category of women with normal cytology after a cervico-vaginal smear (FCV) examination, as well as in those of women with precancerous and cancerous lesions of the cervix [<xref ref-type="bibr" rid="scirp.114765-ref5">5</xref>], in order to be able to develop effective future strategies for the prevention and control of cervical cancer in Congo.</p><p>Thus, this study aimed to determine the prevalence of HPV infections in the departments of Niari and Bouenza, and to identify the oncogenic genotypes present.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Type and Study Population</title><p>This was a cross-sectional descriptive study that took place over a 21-month period from April 2019 to December 2020. The women included in this study were recruited from Dolisie and Nkayi General Hospitals. A total of 207 women had a Pap smear.</p><p>Cytological tests were motivated by certain gynecological problems such as bleeding, vaginal discharge, pelvic pain, pruritus or infertility exploration. Eligible patients included all women who came to the laboratory at these general hospitals for a pap smear, regardless of their medical history during the designated recruitment period. Most of them have never had a medical history regarding cervical cancer or its precancerous lesions. We excluded women who were physically or mentally unable to undergo an interview, women who were pregnant or undergoing known treatment for cervical lesions, or who had refused to participate in the study. The study protocol had been approved by the Health Sciences Research Ethics Board (HSRB): 258/MRSIT/IRSSA/CERSSA.</p></sec><sec id="s2_2"><title>2.2. Collection of Cervical Cells</title><p>During a cervical speculum examination, samples were taken using a cytobrush of the cervix. After scraping, the cells were suspended in special collection vials containing 10 mL of BD SurePath solution<sup>TM</sup> and stored at −20˚C. These samples were used for cytological and molecular analyses.</p></sec><sec id="s2_3"><title>2.3. Cytological Study</title><p>After sampling in the different departments, the samples were sent to the pathology laboratory of the Loandjili General Hospital (HGL) in Pointe-Noire for the cytopathological study. The examination was performed by a pathologist. Results were rendered according to the Classification of the Bethesda 2001 System [<xref ref-type="bibr" rid="scirp.114765-ref9">9</xref>]: Normal or benign reactive cell changes (Normal/BRCC, involving any cervicitis not related to malignancy), atypical squamous cells of undetermined significance (ASCUS), low-grade intraepithelial squamous cell lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) and invasive cervical cancers (ICC).</p></sec><sec id="s2_4"><title>2.4. HPV Detection and Genotyping</title><p>All HPV tests were performed on cervical cell samples stored in a SurePath liquid medium at the Loandjili Hospital laboratory in Pointe Noire. Identification of HPV types was performed by real-time PCR using geneXpert technology (CEPHEID), USA from the Xpert<sup>&#174;</sup> HPV kit.</p><p>The Xpert HPV Assay test is an automated test for the qualitative detection and differentiation of HPV DNA by pooled molecular typing, including high-risk oncogenic HPV. This detection was done by differentiation of the presence of an HPV-16 genotype alone, by grouped genotyping of HPV-18/45 types, grouped genotyping of types 16/18/45 and by detection of high-risk HPV types other than 16, 18, and 45. Extraction, amplification and detection are automated and last 60 minutes.</p></sec><sec id="s2_5"><title>2.5. Statistical Analyses</title><p>Statistical significance between HPV genotypes, cytological status and sociodemographic characteristics was assessed by the exact Fisher test or the Khie-2 test using Epi-Info version 7 software (https://www.cdc.gov/epiinfo/fra/fr_pc.html). Meaning was defined as p &lt; 0.05 for all tests.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Socio-Demographic Characteristics</title><p>A total of 207 cervical samples were analyzed, including 128 from the department of Niari and 79 from the department of Bouenza. The average age of women was 43.67 &#177; 12.31 years and 38.29 &#177; 10.52 years respectively in the departments of Niari and Bouenza with extremes ranging from 18 to 80 years.</p><p>Socio-demographic characteristics are shown in <xref ref-type="table" rid="table1">Table 1</xref>. The main local risk factors related to HPV infection studied in women in these departments were: age, age of first sexual intercourse, number of sexual partners and gestures, taking oral contraceptives, smoking. No significant association was observed between socio-demographic characteristics and genotyping in our study population (p &gt; 0.05).</p></sec><sec id="s3_2"><title>3.2. Cytological Profile</title><p>The cytological profile by department (<xref ref-type="table" rid="table2">Table 2</xref>) was as follows:</p><p>- The department of Niari, with 92.19% (118/128) of cases of normal cytology, 2.34% (3/128) cases of ASCUS, 2.34% (3/128) cases of LSIL and 3.13% (4/128) ICC cases.</p><p>- The Department of Bouenza defined the following cytological profile: 86.07% (68/79) of normal cytology cases, 10.12% (8/79) of ASCUS cases and 3.79% (3/79) of cases were LSIL.</p></sec><sec id="s3_3"><title>3.3. Genotyping of HPV-HR</title><p>A total of 79 of the 207 women in our study tested positive for one or more HPV-HR types. The genotypic distribution by department is shown in <xref ref-type="table" rid="table3">Table 3</xref>. In the department of Niari 48 (37.5%) women tested positive for HPV, and in the department of Bouenza 31 (39.24%) women tested positive for HPV. Multiple infections ranged from two to more than three strains of HPV.</p></sec><sec id="s3_4"><title>3.4. Bivariate Analysis</title><sec id="s3_4_1"><title>3.4.1. HPV Infection and Socio-Demographic Characteristics</title><p>In the department of Niari 43.9% of women with high-risk HPV infection were between 30 and 40 years old. Of the 87.5% of women who had their first sexual intercourse before the age of 18, 37.5% had an HPV-HR infection. Women who had more than 5 sexual partners had 43.75% HPV-HR carrying. HPV-HR infection was observed in 37.07% of women who had more than 5 pregnancies compared to 42.85% in those who had less than 5 pregnancies.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demographic characteristics in the department of Niari and Bouenza</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Characteristics</th><th align="center" valign="middle"  colspan="2"  >Department of Niari</th><th align="center" valign="middle"  colspan="2"  >Department of Bouenza</th></tr></thead><tr><td align="center" valign="middle" >Participants (n)</td><td align="center" valign="middle" >Percentage (%)</td><td align="center" valign="middle" >Effective (n)</td><td align="center" valign="middle" >Percentage (%)</td></tr><tr><td align="center" valign="middle" >Age group (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;30</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >14.06</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.18</td></tr><tr><td align="center" valign="middle" >30 - 40</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >32.03</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.1</td></tr><tr><td align="center" valign="middle" >40 - 50</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >24.21</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >24.05</td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >29.68</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >12.65</td></tr><tr><td align="center" valign="middle" >First sexual intercourse age (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;18</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >87.5</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >62.02</td></tr><tr><td align="center" valign="middle" >≥18</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >12.5</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >37.97</td></tr><tr><td align="center" valign="middle" >Number of Sexual partners</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >51.89</td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.1</td></tr><tr><td align="center" valign="middle" >Number of pregnancies</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >None (0)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.59</td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >27.34</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >40.5</td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >69.53</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >51.89</td></tr><tr><td align="center" valign="middle" >Level of Education</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >10.15</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >18.98</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >66.4</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >59.49</td></tr><tr><td align="center" valign="middle" >University</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >23.43</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >21.51</td></tr><tr><td align="center" valign="middle" >Marital Status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Singles</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >54.68</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >41.77</td></tr><tr><td align="center" valign="middle" >Maried</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >36.71</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >43.03</td></tr><tr><td align="center" valign="middle" >Divorced/Widows</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >8.59</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.18</td></tr><tr><td align="center" valign="middle" >Current Smoke</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >6.25</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.79</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >93.75</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >96.2</td></tr><tr><td align="center" valign="middle" >Alcoholic status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >60.15</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >51.89</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >39.84</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.1</td></tr><tr><td align="center" valign="middle" >Oral Contraception use</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >57.03</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.59</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >42.96</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >92.4</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of the cytological profile by department</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Cytology</th><th align="center" valign="middle"  colspan="2"  >Niari Department</th><th align="center" valign="middle"  colspan="2"  >Bouenza Department</th></tr></thead><tr><td align="center" valign="middle" >Participants (n)</td><td align="center" valign="middle" >Percentage (%)</td><td align="center" valign="middle" >Participants (n)</td><td align="center" valign="middle" >Percentage (%)</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >118</td><td align="center" valign="middle" >92.19</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >86.07</td></tr><tr><td align="center" valign="middle" >Ascus</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.34</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10.12</td></tr><tr><td align="center" valign="middle" >LSIL</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.34</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.79</td></tr><tr><td align="center" valign="middle" >HSIL</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >ICC</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.13</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr></tbody></table></table-wrap><p>ASCUS: Atypies of squamous cells of undetermined significance. LSIL: Low-grade squamous intraepithelial lesion. HSIL: High-grade scaly intraepithelial lesion. ICC: Invasive cervical carcinoma.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Prevalence of HPV types by department</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >G&#233;notypes HPV</th><th align="center" valign="middle"  colspan="2"  >Niari Department (N = 128)</th><th align="center" valign="middle"  colspan="2"  >Bouenza Department (N = 79)</th></tr></thead><tr><td align="center" valign="middle" >Participants (n)</td><td align="center" valign="middle" >Percentage (%)</td><td align="center" valign="middle" >Participants (n)</td><td align="center" valign="middle" >Percentage (%)</td></tr><tr><td align="center" valign="middle" >HPV−</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >60.75</td></tr><tr><td align="center" valign="middle" >HPV+</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.24</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >18.75</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >21.51</td></tr><tr><td align="center" valign="middle" >18/45</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.26</td></tr><tr><td align="center" valign="middle" >16/18/45</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.56</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.52</td></tr><tr><td align="center" valign="middle" >16/Other</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >6.24</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.86</td></tr><tr><td align="center" valign="middle" >Other</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >7.81</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.04</td></tr></tbody></table></table-wrap><p>No statistically significant differences were observed between socio-demographic characteristics and HPV-HR genotyping (p &gt; 0.05). All results are reported in <xref ref-type="table" rid="table4">Table 4</xref>.</p><p>In the department of Bouenza, it was observed a portage of HPV-HR infection in 39.47% of cases in 30 - 40 year olds. 38.77% of HPV-HR infection was observed in women who had their first sexual intercourse before the age of 18. Women who had more than 5 sexual partners reported an infection 39.47% while those who had more than 5 pregnancies were infected only to the rate of 36.58%.</p><p>No statistically significant association was observed between socio-demographic characteristics and HPV genotyping (p &gt; 0.05). All the results are reported in <xref ref-type="table" rid="table5">Table 5</xref>.</p></sec><sec id="s3_4_2"><title>3.4.2. HPV Infection and Cytological Diagnosis</title><p>Bivariate analysis between HPV-HR infection carriage and cytological profile in Niari department showed that 85.41% of women with normal cytology had HPV-HR infection. Carriage of HPV-HR infection was 4.16% in women with ASCUS and 10.41% in those with cytological abnormalities, including 2.08% LSIL and 8.33% ICC. A statistically significant association was observed (p = 0.013). <xref ref-type="table" rid="table6">Table 6</xref> shows the prevalence of HPV-HR infection according to the cytological profile in the department of Niari.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Socio-demographic characteristics and HPV infection in the department of Niari</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Characteristics</th><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Participants</th><th align="center" valign="middle"  colspan="4"  >Department of Niari</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >HPV (+)</td><td align="center" valign="middle"  colspan="2"  >HPV (−)</td></tr><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >Age group (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;30</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >14.06</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >22.22</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >77.77</td></tr><tr><td align="center" valign="middle" >30 - 40</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >32.03</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >43.9</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >56.09</td></tr><tr><td align="center" valign="middle" >40 - 50</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >24.21</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >41.93</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >58.06</td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >29.68</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >34.21</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >65.78</td></tr><tr><td align="center" valign="middle" >First sexual intercourse age (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;18</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >87.5</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >62.5</td></tr><tr><td align="center" valign="middle" >≥18</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >12.5</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >62.5</td></tr><tr><td align="center" valign="middle" >Number of Sexual partners</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >35.41</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >64.58</td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >43.75</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >56.25</td></tr><tr><td align="center" valign="middle" >Number of pregnancies</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >None (0)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >27.34</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >42.85</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >57.14</td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >69.53</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >37.07</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >62.92</td></tr><tr><td align="center" valign="middle" >Level of Education</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >10.15</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >53.84</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >46.15</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >66.4</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >32.94</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >67.05</td></tr><tr><td align="center" valign="middle" >University</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >23.43</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >43.33</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >56.66</td></tr><tr><td align="center" valign="middle" >Marital Status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Singles</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >54.68</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >37.14</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >62.85</td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >36.71</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >36.17</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >63.82</td></tr><tr><td align="center" valign="middle" >Divorced/Widows</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >8.59</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >54.54</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >45.,45</td></tr><tr><td align="center" valign="middle" >Current Smoke</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >6.25</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >93.75</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >38.33</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >61.66</td></tr><tr><td align="center" valign="middle" >Alcoholic status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >60.15</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >38.96</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >61.03</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >39.84</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >35.29</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >64.7</td></tr><tr><td align="center" valign="middle" >Oral Contraception use</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >57.03</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >29.09</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >70.9</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >42.96</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >43.83</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >56.16</td></tr></tbody></table></table-wrap><p>p &gt; 0.05.</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Socio-demographic characteristics and HPV infection in the department of Bouenza</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Characteristics</th><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Participants</th><th align="center" valign="middle"  colspan="4"  >Department of Bouenza</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >HPV (+)</td><td align="center" valign="middle"  colspan="2"  >HPV (−)</td></tr><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >Age group (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;30</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.18</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >66.66</td></tr><tr><td align="center" valign="middle" >30 - 40</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.1</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >39.47</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >60.52</td></tr><tr><td align="center" valign="middle" >40 - 50</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >24.05</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >42.1</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >57.89</td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >12.65</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >60</td></tr><tr><td align="center" valign="middle" >First sexual intercourse age (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;18</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >62.02</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >38.77</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >61.22</td></tr><tr><td align="center" valign="middle" >≥18</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >37.97</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >60</td></tr><tr><td align="center" valign="middle" >Number of Sexual partners</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >51.89</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >39.02</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >60.97</td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.1</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >39.47</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >60.52</td></tr><tr><td align="center" valign="middle" >Number of pregnancies</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >None (0)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.59</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >66.66</td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >40.5</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >43.75</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >56.25</td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >51.89</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >36.58</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >63.41</td></tr><tr><td align="center" valign="middle" >Level of Education</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >18.98</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >66.66</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >59.49</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >42.55</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >57.44</td></tr><tr><td align="center" valign="middle" >University</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >21.51</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >35.29</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >64.7</td></tr><tr><td align="center" valign="middle" >Marital Status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Singles</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >41.77</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >39.39</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >60.6</td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >43.03</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >38.23</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >61.76</td></tr><tr><td align="center" valign="middle" >Divorced/Widows</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.18</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >41.66</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >58.33</td></tr><tr><td align="center" valign="middle" >Current Smoke</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.79</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >96.2</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >36.84</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >63.15</td></tr><tr><td align="center" valign="middle" >Alcoholic status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >51.89</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >46.34</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >53.65</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.1</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >31.57</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >68.42</td></tr><tr><td align="center" valign="middle" >Oral Contraception use</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.59</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >66.66</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >92.4</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >39.72</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >60.27</td></tr></tbody></table></table-wrap><p>p &gt; 0.05.</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Genotyping of HPV-HR and cytological status in the department of Niari</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >HPV types</th><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle"  colspan="10"  >Cytological profil</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Department of Niari</td><td align="center" valign="middle"  colspan="2"  >Normal</td><td align="center" valign="middle"  colspan="2"  >ASCUS</td><td align="center" valign="middle"  colspan="2"  >LSIL</td><td align="center" valign="middle"  colspan="2"  >HSIL</td><td align="center" valign="middle"  colspan="2"  >ICC</td></tr><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >HPV−</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >96.25</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.25</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >HPV+</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >85.41</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.16</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8.33</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >18.75</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >45.82</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td></tr><tr><td align="center" valign="middle" >18/45</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.16</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td></tr><tr><td align="center" valign="middle" >16/18/45</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.56</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.16</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >16/Other</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >6.24</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12.49</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td></tr><tr><td align="center" valign="middle" >Other</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >7.81</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >18.74</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.08</td></tr></tbody></table></table-wrap><p>P = 0.013.</p><p>Bivariate analysis between HPV-HR infection carriage and cytological profile in Bouenza department showed that 80.64% of women with normal cytology had HPV-HR infection. Carriage of HPV-HR infection was 9.67% in women with ASCUS and LSIL respectively. A statistically significant association was observed (p = 0.039). <xref ref-type="table" rid="table7">Table 7</xref> shows the prevalence of HPV-HR infection according to the cytological profile in the department of Bouenza.</p></sec></sec></sec><sec id="s4"><title>4. Discussion</title><p>Epidemiological data on HPV strain genotyping and cervical cancer remain fragmented in the Republic of the Congo. This information on HPV infections is essential in the process of implementing a national HPV control program. The objective of this work was to determine the prevalence of HPV infections in two departments of the Congo, and to identify the oncogenic genotypes according to cytological status.</p><p>The average age of the women participating in this study was 43.67 &#177; 12.31 years in Niari and 38.29 &#177; 10.52 in Bouenza with age intervals ranging from 18 to 80 years.</p><p>Our results for the department of Niari are similar to those of Boumba et al. (2015), Loubanou Tchibinda et al. (2020) and Mehendar Porika et al. (2011) which reported the average ages of 44.3 &#177; 8.2 years, 43.74 &#177; 10.30 years and 47.9 &#177; 1.8 years [<xref ref-type="bibr" rid="scirp.114765-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.114765-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.114765-ref12">12</xref>] respectively. On the other hand, our average age for the department of Bouenza is also in agreement with that of Reesink-Peters et al. (2004) who obtained an average age population of 37 years in the Netherlands [<xref ref-type="bibr" rid="scirp.114765-ref13">13</xref>]. These similarities in the average age of the study population could be explained by the fact that the dynamics of the Congolese population have remained the same for the last 5 years.</p><p>In the departments of Niari and Bouenza, 87.5% and 62.02% of women had their first sexual intercourse before the age of 18, respectively. These results are</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Genotyping of HPV-HR and cytological status in the department of Bouenza</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >types HPV</th><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle"  colspan="10"  >Cytology</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Department of Bouenza</td><td align="center" valign="middle"  colspan="2"  >Normal</td><td align="center" valign="middle"  colspan="2"  >ASCUS</td><td align="center" valign="middle"  colspan="2"  >LSIL</td><td align="center" valign="middle"  colspan="2"  >HSIL</td><td align="center" valign="middle"  colspan="2"  >ICC</td></tr><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >HPV−</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >60.75</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >89.58</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10.41</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >HPV+</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.24</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >80.64</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >9.67</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >9.67</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >21.51</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >48.38</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6.44</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >18/45</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.26</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >16/18/45</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.53</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >16/Other</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.88</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >19.35</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Other</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.06</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >9.67</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr></tbody></table></table-wrap><p>p = 0.039.</p><p>slightly lower than those of Catarino et al. (2016) in Cameroon, Arora et al. (2005) in England [<xref ref-type="bibr" rid="scirp.114765-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.114765-ref15">15</xref>], who had found the age of 19 in the majority of their studies. On the other hand Shin et al. (2019) had reported an average age of 17 years in India [<xref ref-type="bibr" rid="scirp.114765-ref16">16</xref>]. The precocity of the age of the first sexual intercourse seems to be explained by the culture and the sociology of the Congolese population which is very modern, young and very Westernized in mentality.</p><p>In the present study, 25% of women in the department of Niari and 48.1% of that of Bouenza had more than 5 sexual partners. These results can be superimposed on that of Carol Chelimo [<xref ref-type="bibr" rid="scirp.114765-ref17">17</xref>]. Regardless of the department, more than 51% of the women had at least 5 pregnancies. This result is close to that of Olivier et al. (2005) who obtained 59.6% in an epidemiological and cytopathological profile study of dysplastic lesions of the cervix in Congo-Kinshasa [<xref ref-type="bibr" rid="scirp.114765-ref18">18</xref>]. The modernization of manners and the precocity of the age of the first sexual intercourse are as many factors explaining the multiplicity of sexual partners. However, the level of poverty in the population also plays a major role in this sense.</p><p>The cytological profile in the departments of Niari and Bouenza was respectively 92.19% and 86.07% of normal cytology; 2.34% and 10.12% ASCUS; 2.34% and 3.79% LSIL. Only 3.13% of CCI was found in the department of Niari. Our results are similar to those of Kasap et al. (2011) who found in their studies a rate of 10.85% of abnormal pap smears in Turkey [<xref ref-type="bibr" rid="scirp.114765-ref19">19</xref>], and Takamatsu et al. (2017) reported a prevalence of 14.57% of cytological abnormalities in Nigeria [<xref ref-type="bibr" rid="scirp.114765-ref20">20</xref>].</p><p>On the other hand, Vjosa et al. (2017) had reported much higher results with prevalences of 49.93% in Macedonia [<xref ref-type="bibr" rid="scirp.114765-ref21">21</xref>]. While cervical cancer is the 2nd cancer in Congolese women, only 12.35% of our study population had a cytological abnormality. This relatively low rate could be explained by the young nature of our population which is able thanks to a strong local immunity to spontaneously eliminate the virus [<xref ref-type="bibr" rid="scirp.114765-ref22">22</xref>].</p><p>The prevalence of HPV-HR infection was 37.5% and 39.24% in the departments of Niari and Bouenza respectively. These results are similar to those of BOUMBA et al. (2015) and LOUBANOU et al. (2020) which reported prevalences of 41.1% and 41.5% respectively [<xref ref-type="bibr" rid="scirp.114765-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.114765-ref24">24</xref>]. On the other hand, they do not agree with Gordana Kovacevic’s study in Serbia which was 51.8% [<xref ref-type="bibr" rid="scirp.114765-ref25">25</xref>], and are also much higher than those described in the majority of European studies which are between 11.3% and 18.3% [<xref ref-type="bibr" rid="scirp.114765-ref26">26</xref>]. Our HPV prevalence observed in the two departments, although low compared to certain African countries, show higher proportions than the African average. The types of HPV-HR observed in this study allow us to confirm the importance of screening in these populations studied.</p><p>The prevalence of HPV infection in women without cervical lesions was 85.41% and 80.64% respectively in Niari and Bouenza. These HPV-HR frequencies in women without cervical lesions were well above the global average (10.4%), higher than the average in the sub-Saharan Africa region (22.1%) and finally higher than the Boumba et al. study (2015) (23.5%) [<xref ref-type="bibr" rid="scirp.114765-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.114765-ref27">27</xref>].</p><p>Indeed, the exposure of our study population to many risk factors for HPV infection and risky sexual behaviors could explain this high rate of HPV infection observed in these two departments. These results also show the lack of knowledge of HPV infection in our population, which is rarely detected. The lack of a national screening program and awareness campaigns could also explain this lack of knowledge and high rates of HPV-HR in this category of women. On the other hand, 14.54% and 19.34% of women with HPV-HR infection had at least one cytological abnormality in the departments of Niari and Bouenza respectively. These results in agreement with the majority of studies in the literature prove the lack of information and awareness among populations about this pathology and suggest that women who consult are potentially at risk because they do so for the most part only as a result of a gynecological problem.</p><p>In both departments, HPV 16 was the most prevalent genotype, 45.82% in Niari and 48.38% in Bouenza. These results are in agreement with the study by LOUBANOU et al. (2020) which placed HPV 16 in first place, and other types of HPV in second place [<xref ref-type="bibr" rid="scirp.114765-ref24">24</xref>]. They also agree with the study by BOUMBA et al. (2015) on the distribution of HPV whose genotypes HPV 16 (20.6%) and HPV 33 (14.3%) were the most prevalent [<xref ref-type="bibr" rid="scirp.114765-ref23">23</xref>]. Although these results allowed us to obtain the prevalence of HPV 16 isolation genotypes, the GeneXpert technique used in this study did not allow us to determine the prevalence of other HPV types, due to the fact that this typing is pooled.</p><p>High-risk oncogenic HPV genotypes have been observed in low-grade, high-grade and invasive cervical cancers. These results are consistent with the study by N. El Gnaoui et al. [<xref ref-type="bibr" rid="scirp.114765-ref28">28</xref>].</p><p>These high prevalences confirm how aggressive HPV 16 is compared to other types and reinforce the idea of establishing better epidemiological monitoring of the populations of these two departments in order to prevent the persistence and progression of these HPV-HR to cervical cancer [<xref ref-type="bibr" rid="scirp.114765-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.114765-ref24">24</xref>].</p><p>It should be noted that this study, despite its limitations related to sample size, presents a pragmatic situational analysis of the molecular epidemiology of this virus in the two departments concerned.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The present study made it possible to define the cytological profile of precancerous and cancerous lesions of the cervix in the departments of Niari and Bouenza. Our results showed that despite the absence of cytological lesions, more than 50% of HPV-HR were identified in women with normal cytology with HPV type 16 as the most prevalent. This work is a reminder of the importance of the urgent establishment of a national program to fight against this cancer and HPV infections in Congo. However, future studies are needed to map HPV-HR throughout the national territory.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We would like to thank the HDL Laboratory Management of the Marie Madeleine GOMBES foundation. Our thanks also go to Doctor Francis TCHYCAYA for the multifaceted support.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Nganga, P.C., Boumba, L.M.A., Lemba Tsimba, C.P., Loubanou Tchibinda, F.G., Bissala Nkounkou, R.B., Ataboho, E.E., Loubano-Voumbi, G. and Moukassa, D. (2022) Prevalence and Genotyping of Human Papillomavirus among Women in the Departments of Niari and Bouenza, Republic of the Congo. Journal of Biosciences and Medicines, 10, 64-77. https://doi.org/10.4236/jbm.2022.101007</p></sec></body><back><ref-list><title>References</title><ref id="scirp.114765-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kovacevic, G., Milosevic, V., Knezevic, P., et al. (2019) Prevalence of Oncogenic Human Papillomavirus and Genetic Diversity in the L1 Gene of HPV16 HPV 18 HPV31 and HPV33 Found in Women from Vojvodina Province Serbia. Biologicals, 58, 57-63. https://doi.org/10.1016/j.biologicals.2019.02.001</mixed-citation></ref><ref id="scirp.114765-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bosch, F.X., Burchell, A.N., Schiffman, M., et al. (2008) Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine, 26, K1-K16. https://doi.org/10.1016/j.vaccine.2008.05.064</mixed-citation></ref><ref id="scirp.114765-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Smith, J.S., Lindsay, L., Hoots, B., et al. (2007) Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Lesions: A Meta-Analysis Update. International Journal of Cancer, 121, 621-632. https://doi.org/10.1002/ijc.22527</mixed-citation></ref><ref id="scirp.114765-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">El Gnaoui, N., Joutei, H.A.H., Saile, R., et al. (2013) Molecular Diagnosis of Human Papillomavirus Infection in Precancerous Lesions of the Cervix. African Journal of Cancer, 5, 73-78. https://doi.org/10.1007/s12558-013-0248-y</mixed-citation></ref><ref id="scirp.114765-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tchibinda, F.G.L., Boumba, L.M.A. and Ngatali, S.F.C. (2020) Molecular Characterization of Oncogenic HPVs by Genexpertin Congolese Women in the Cities of Pointe-Noire and Dolisie. Journal of Global Biosciences, 9, 7980-7987.</mixed-citation></ref><ref id="scirp.114765-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Boumba, L.M.A., Qmichou, Z., Mouallif, M., et al. (2015) Distribution of Human Papillomavirus Genotypes by Cervical Cytological Status in Women Attending Loandjili General Hospital, Pointe-Noire, South-West Congo (Brazzaville). Journal of Medical Virology, 87, 1769-1776. https://doi.org/10.1002/jmv.24221</mixed-citation></ref><ref id="scirp.114765-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Denis, F., Hanz, S. and Alain, S. (2008) Clearance, Persistence and Recurrence of Papillomavirus Infection. Gynecology Obstetrics &amp; Fertility, 36, 430-440. https://doi.org/10.1016/j.gyobfe.2008.02.008</mixed-citation></ref><ref id="scirp.114765-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zejnullahu, V.A. and Valon, A. (2017) Correlation of hTERT Expression with Cervical Cytological Abnormalities and HPV Infection. Medical Sciences, 3, 143-151.</mixed-citation></ref><ref id="scirp.114765-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Takamatsu, R., Nabandith, V., Pholsena, V., et al. (2017) Cervical Cytology and HPV among Asymptomatic Female Volunteers in Vietnam, Lao PDR. BMC Cancer, 17, Article No. 872. https://doi.org/10.1186/s12885-017-3900-6</mixed-citation></ref><ref id="scirp.114765-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kasap, B., Yetimalar, H., Keklik, A., et al. (2011) Prevalence and Risk Factors for Human Papillomavirus DNA in Cervical Cytology. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 159, 168-171. https://doi.org/10.1016/j.ejogrb.2011.06.021</mixed-citation></ref><ref id="scirp.114765-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Olivier, N., Fabrice, K., Albert, et al. (2021) Epidemiological and Cytopathological Profile of Dysplastic Lesions of the Cervix in South Kivu/Congo. Open Journal of Obstetrics and Gynecology, 11, 162-182. https://doi.org/10.4236/ojog.2021.112018</mixed-citation></ref><ref id="scirp.114765-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chelimo, C., Wouldes, T.A., et al. (2013) Risk Factors for and Prevention of Human Papillomaviruses (HPV), Genital Warts and Cervical Cancer. Journal of Infection, 66, 207-217. https://doi.org/10.1016/j.jinf.2012.10.024</mixed-citation></ref><ref id="scirp.114765-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Shin, S.S., Carpenter, C.L., Ekstrand, M.L., et al. (2019) Cervical Cancer Awareness and Presence of Abnormal Cytology in HIV-Infected Women on Antiretroviral Therapy in Rural Andhra Pradesh, India. International Journal of STDs and AIDS, 30, 586-595. https://doi.org/10.1177/0956462419825950</mixed-citation></ref><ref id="scirp.114765-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Arora, R., Kumar, A., Prusty, et al. (2005) Prevalence of High-Risk Human Papillomavirus (HPV-HR) Types 16 and 18 in Healthy Women with a Cytologically Negative Smear. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 121, 104-109. https://doi.org/10.1016/j.ejogrb.2004.11.025</mixed-citation></ref><ref id="scirp.114765-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Catarino, R., Vassilakos, P., Tebeu, et al. (2016) Risk Factors Associated with the Prevalence of Human Papillomavirus and Cervical Neoplasia in Cameroonian Women. Cancer Epidemiology, 40, 60-66. https://doi.org/10.1016/j.canep.2015.11.008</mixed-citation></ref><ref id="scirp.114765-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Reesink-Peters, J.F.S., Roderick, H.J.B., Thomas, G.S., et al. (2004) Elevated hTERT mRNA Levels: A Potential Determinant of Bronchial Squamous Cell Carcinoma (in Situ). International Journal of Cancer, 109, 412-417. https://doi.org/10.1002/ijc.11732</mixed-citation></ref><ref id="scirp.114765-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Porika, M., Radhika, T., Anwar, M., et al. (2011) Evaluation of Reverse Transcriptase of Human Serum Telomerase as a Novel Marker of Cervical Cancer. The International Journal of Biological Markers, 26, 22-26. https://doi.org/10.5301/JBM.2011.6352</mixed-citation></ref><ref id="scirp.114765-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Loubano-Voumbi, G., et al. (2020) Distribution of HPV Strains in HIV-Positive Women in Pointe-Noire and Dolisie (Congo). International Journal of Virology and Molecular Biology, 9, 45-49.</mixed-citation></ref><ref id="scirp.114765-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Boumba, L.M.A., Hilali, L., Mouallif, M., et al. (2014) Specific Genotypes of Human Papillomavirus in 125 High-Grade Squamous Lesions and Invasive Cervical Cancer Cases from Congolese Women. BMC Public Health, 14, Article No. 1320. https://doi.org/10.1186/1471-2458-14-1320</mixed-citation></ref><ref id="scirp.114765-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Apgar, B.S., Zoschnick, L., Wright, T.C., et al. (2003) The 2001 Bethesda System Terminology. American Family Physician, 68, 1992-1998.</mixed-citation></ref><ref id="scirp.114765-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bruni, L., Barrionuevo-Rosas, L., Albero, G., et al. (2018) ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases Worldwide. Synthesis Report of 27 July 2017.</mixed-citation></ref><ref id="scirp.114765-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bruni, L., Albero, G., Serrano, B., et al. (2021) ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Congo. Summary Report 22 October.</mixed-citation></ref><ref id="scirp.114765-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">De Vuyst, H., Alemany, L., Lacey, C., et al. (2013) The Burden of Human Papillomavirus Infections and Related Diseases in Sub-Saharan Africa. Vaccine, 31, F32-F46. https://doi.org/10.1016/j.vaccine.2012.07.092</mixed-citation></ref><ref id="scirp.114765-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2019) Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. International Journal of Cancer, 144, 1941-1953. https://doi.org/10.1002/ijc.31937</mixed-citation></ref><ref id="scirp.114765-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Sangwa-Lugoma, G., Ramanakumar, A.V., Mahmud, S., et al. (2011) Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Women from a Sub-Saharan African Community. Sexually Transmitted Diseases, 38, 308-315. https://doi.org/10.1097/OLQ.0b013e3181fc6ec0</mixed-citation></ref><ref id="scirp.114765-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Soerjomataram, D.R., Eser, S., Mathers, C., et al. (2012) Global Cancer Incidence and Mortality: Sources, Methods and Key Models. Globocan.</mixed-citation></ref><ref id="scirp.114765-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Anorlu, R.I. (2008) Cervical Cancer: The Sub-Saharan African Perspective. Reproductive Health Matters, 16, 41-49. https://doi.org/10.1016/S0968-8080(08)32415-X</mixed-citation></ref><ref id="scirp.114765-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Global Incidence and Mortality for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492</mixed-citation></ref></ref-list></back></article>